Are Small-Cap Stocks More Profitable in Emerging Markets?
The classic small-cap premium shows modest support in emerging markets, but illiquidity and domestic growth play larger roles than size alone.

Image by Gerd Altmannfrom Pixabay
The small-cap premium theory holds that smaller companies tend to generate higher long-term returns than larger ones. Academic work dating to the early 1980s first documented this pattern in developed markets. Yet its strength and consistency weaken when applied to emerging markets, where different economic forces dominate.
Here is the kicker: Data from major index providers show a modest positive premium for small-caps in emerging markets over long periods, but it is smaller and more variable than the classic developed-market version. Investors must therefore compare returns, risks, and structural drivers side by side before allocating.
Table of Contents
- Understanding the Small-Cap Premium Theory
- The Small-Cap Premium in Developed Markets
- Small-Cap Performance in Emerging Markets
- Why Emerging Markets Differ from Developed Ones
- Risks and Practical Considerations
- Side-by-Side Comparison: Small-Caps in EM vs DM
Understanding the Small-Cap Premium Theory
The theory originated with Rolf Banz’s 1981 study showing smaller US stocks outperformed larger ones on a risk-adjusted basis. Eugene Fama and Kenneth French later incorporated the size factor (SMB: small minus big) into their three-factor model. Small firms were seen as riskier because of higher business uncertainty, limited access to capital, and lower analyst coverage.
What changed next is that researchers expanded tests globally. The premium appeared in many developed markets but proved sensitive to time periods and definitions of “small.” Emerging-market versions of the model often find the size factor weaker or subsumed by other risks such as illiquidity.
Why this matters is that the premium is not a free lunch. It compensates for genuine economic frictions rather than representing a market inefficiency that can be arbitraged away easily.
The Small-Cap Premium in Developed Markets
In the United States, the Fama-French small-research index returned 11.7% annualized from 1927 to 2023 versus 10.1% for large-research stocks, a 1.6 percentage-point premium. Similar patterns held in other developed markets during the 20th century. Academic databases from Kenneth French confirm positive SMB returns across North America, Europe, and Asia-Pacific ex-Japan for multi-decade windows.
Yet the premium has faded sharply in recent decades. Over the past 20 years through 2023, US small-caps underperformed large-caps by about 1.2 percentage points annually. Mega-cap technology concentration and the rise of passive indexing have been cited as structural headwinds.
Advertisement
The bottom line for developed markets is that the size premium remains visible over very long horizons but has been unreliable since the mid-2010s.
Small-Cap Performance in Emerging Markets
Evidence in emerging markets is more nuanced. GMO’s analysis of MSCI data from January 2000 to September 2018 shows EM small-caps outperforming the broad MSCI EM index (large-cap proxy) by roughly 0.5% annualized. Morgan Stanley research covering the post-global-financial-crisis period from December 2008 to July 2017 reports a stronger 2.6% annualized edge for the MSCI EM Small Cap Index, accompanied by roughly one percentage point lower volatility.
MSCI’s own factsheet places long-term annualized net returns for the EM Small Cap Index at 5.85% since May 1994. Recent calendar years have been mixed: small-caps posted strong gains in 2023 (23.92%) while trailing in others such as 2024. The premium therefore exists but fluctuates with local growth cycles.
Studies applying Fama-French factors to emerging-market universes find the size effect present yet often smaller than the value effect. Illiquid stocks—regardless of market cap—drive much of the observed outperformance.
Why Emerging Markets Differ from Developed Ones
Emerging-market small-caps operate in economies shifting from export-led to domestic-consumption models. They carry nearly double the weight in healthcare, industrials, and consumer discretionary versus the broad EM index and far less in energy or IT. This domestic tilt aligns with accelerating GDP growth differentials that historically favor EM equities.
Liquidity is the dominant differentiator. GMO’s matrix reveals that liquid small-caps underperformed the MSCI EM benchmark by 4.8% annualized, while illiquid names (small or large) added nearly 3%. Lower analyst coverage and thinner trading volumes create genuine information and trading-cost risks that command compensation.
Advertisement
Governance standards and ownership concentration also vary widely across EM countries. These factors can amplify or mute the size effect depending on the specific market and regulatory environment.
Risks and Practical Considerations
Small-caps everywhere exhibit higher volatility than large-caps. In emerging markets the gap widens because of currency swings, political events, and shallower capital markets. Maximum drawdowns for the MSCI EM Small Cap Index have historically exceeded those of the broad index during stress periods.
Implementation costs matter. Bid-ask spreads are wider, and institutional flows can move prices more dramatically. Active managers with on-the-ground research have historically added more value in this segment than in large-cap EM, but passive replication is harder and costlier.
Diversification benefits exist. EM small-caps show lower correlation to developed-market large-caps than EM large-caps do, offering portfolio-level risk reduction when combined thoughtfully.
Side-by-Side Comparison: Small-Caps in EM vs DM
The table below summarizes key dimensions based on cited index and research sources.
| Metric / Period | Developed Markets | Emerging Markets | Source |
|---|---|---|---|
| Long-term size premium | +1.6% pa (US 1927–2023) | +0.5% to +2.6% pa (varies by window) | Morningstar / GMO / Morgan Stanley |
| Recent 20-year premium | Negative (~–1.2% pa) | Modest positive in select sub-periods | Fama-French / MSCI |
| Volatility differential | Higher for small-caps | Small-caps sometimes lower than broad EM | MSCI / Morgan Stanley |
| Main driver | Historical risk & inefficiency | Illiquidity + domestic growth tilt | GMO |
| Analyst coverage | Moderate | Very low (creates alpha potential) | Industry data |
Trade-offs are clear. Developed-market small-caps offer greater liquidity and transparency but have seen their premium erode. Emerging-market small-caps provide exposure to faster-growing economies and domestic themes yet demand tolerance for higher operational friction and country-specific risks.
The bottom line is that small-cap stocks are not uniformly more profitable in emerging markets. A modest premium appears in long-run data, but success hinges on time horizon, liquidity management, and the ability to navigate local conditions. Investors comparing the two universes should focus on portfolio-level diversification rather than chasing any single factor in isolation.
Source: https://www.gmo.com/globalassets/articles/insights/emerging-equity/2019/bg_em-illiquid_7-19.pdf
Continue reading
Jump back to the Market Lens homepage for the latest coverage.
Go to Market LensLatest Articles
View all01 | Market Pulse
CSE close: ASPI -0.39%, breadth negative on 2026-06-02
Trade date June 02, 2026
02 | Market Pulse
CSE close: ASPI +0.11%, breadth positive on 2026-05-27
Trade date May 27, 2026
03 | Market Pulse
CSE close: ASPI -0.85%, breadth negative on 2026-05-26
Trade date May 26, 2026
04 | Market Pulse
CSE close: ASPI +1.98%, breadth positive on 2026-05-25
Trade date May 25, 2026